Join
Live feed
·
PRReleasevia Quantisnow
NeOnc Technologies Holdings Inc. logo

NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

ByQuantisnow·Wall Street's wire, on your screen.
NTHI· NeOnc Technologies Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NTHI (NeOnc Technologies Holdings Inc.) and more on Quantisnow.